Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil H Bander

Showing results (21-30 of 85) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2004
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Electrophoresis|August 9, 2013
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell captureChao Huang, Steven M Santana, He Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancerNeil H Bander, Matthew I Milowsky, David M Nanus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicityShankar Vallabhajosula, Stanley J Goldsmith, Lale Kostakoglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2003
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumorPeter M Smith-Jones, Shankar Vallabhajosula, Vincent Navarro, et al.
Archives of Pathology & Laboratory Medicine|October 29, 2011
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiformeA Gabriella Wernicke, Mark A Edgar, Ehud Lavi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2010
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivoJason P Holland, Vadim Divilov, Neil H Bander, et al.
Molecular Cancer Therapeutics|May 18, 2005
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapyJason J Christiansen, Sigrid A Rajasekaran, Landon Inge, et al.
Clinical Genitourinary Cancer|May 30, 2006
Clinical utility of radiolabeled monoclonal antibodies in prostate cancerKevin A David, Matthew I Milowsky, Lale Kostakoglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 13, 2011
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PETAlessandro Ruggiero, Jason P Holland, Tvrtko Hudolin, et al.
Pageof 9

Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2004
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Electrophoresis|August 9, 2013
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell captureChao Huang, Steven M Santana, He Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancerNeil H Bander, Matthew I Milowsky, David M Nanus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicityShankar Vallabhajosula, Stanley J Goldsmith, Lale Kostakoglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2003
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumorPeter M Smith-Jones, Shankar Vallabhajosula, Vincent Navarro, et al.
Archives of Pathology & Laboratory Medicine|October 29, 2011
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiformeA Gabriella Wernicke, Mark A Edgar, Ehud Lavi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2010
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivoJason P Holland, Vadim Divilov, Neil H Bander, et al.
Molecular Cancer Therapeutics|May 18, 2005
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapyJason J Christiansen, Sigrid A Rajasekaran, Landon Inge, et al.
Clinical Genitourinary Cancer|May 30, 2006
Clinical utility of radiolabeled monoclonal antibodies in prostate cancerKevin A David, Matthew I Milowsky, Lale Kostakoglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 13, 2011
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PETAlessandro Ruggiero, Jason P Holland, Tvrtko Hudolin, et al.
Pageof 9